美国与骨移植产品相关的全国性结核暴发:暴发报告
2021年美国CDC与FDA调查了一起与单例 deceased donor 来源含活细胞骨移植产品相关的结核暴发。154单位产品中136单位(88%)植入113例受者,87例(77%)有结核病微生物学或影像学证据,8例死亡。作者认为所有拟捐献组织与器官者应常规评估结核风险因素与临床表现,存在时应强烈考虑实验室检测。
要点
- 单例 deceased donor 来源骨移植产品导致113例受者中87例(77%)患结核病,8例死亡。
- 所有105例存活受者在植入后中位69天(IQR 56–81)开始抗结核治疗。
- 作者认为所有拟捐献组织与器官者应常规评估结核风险因素与临床表现,存在时应强烈考虑实验室检测。
核心结论
- 供者来源结核分枝杆菌经骨同种异体移植传播导致大量发病与死亡。
- 所有拟捐献组织与器官者应常规评估结核风险因素与临床表现。
- 存在结核风险因素与临床表现时,应强烈考虑进行结核分枝杆菌实验室检测。
研究设计与样本
- 暴发报告:CDC与州及地方卫生部门、医疗机构合作追查并封存召回批次未使用产品,通知、评估并治疗所有已识别产品受者。
- CDC与FDA调查人员审查供者筛查与组织处理过程。
- 对召回批次及其他供者批次未使用产品行实时PCR与培养检测结核分枝杆菌,并对未使用产品与受者分离株行系统发育分析。
主要发现
- 组织供者为80岁男性,有未被识别的结核风险因素、症状与体征。
- 2021年3月1日至4月2日,154单位含活细胞骨同种异体移植产品被配送至20个州的37家医院与门诊手术中心。
- 2021年3月3日至6月1日,136单位(88%)植入18个州的113例24–87岁受者(部分个体接受多单位)。
- 剩余18单位(12%)被定位并封存。
- 113例已识别受者中87例(77%)有结核病微生物学或影像学证据。
临床怎么用
- 作者认为所有拟捐献组织与器官者应常规评估结核风险因素与临床表现。
- 作者认为存在结核风险因素与临床表现时,应强烈考虑进行结核分枝杆菌实验室检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycobacterium tuberculosis transmission through solid organ transplantation has been well described, but transmission through transplanted tissues is rare. We investigated a tuberculosis outbreak in the USA linked to a bone graft product containing live cells derived from a single deceased donor. METHODS: In this outbreak report, we describe the management and severity of the outbreak and identify opportunities to improve tissue transplant safety in the USA. During early June, 2021, the US Centers for Disease Control and Prevention (CDC) worked with state and local health departments and health-care facilities to locate and sequester unused units from the recalled lot and notify, evaluate, and treat all identified product recipients. Investigators from CDC and the US Food and Drug Administration (FDA) reviewed donor screening and tissue processing. Unused product units from the recalled and other donor lots were tested for the presence of M tuberculosis using real-time PCR (rt PCR) assays and culture. M tuberculosis isolates from unused product and recipients were compared using phylogenetic analysis. FINDINGS: The tissue donor (a man aged 80 years) had unrecognised risk factors, symptoms, and signs consistent with tuberculosis. Bone was procured from the deceased donor and processed into 154 units of bone allograft product containing live cells, which were distributed to 37 hospitals and ambulatory surgical centres in 20 US states between March 1 and April 2, 2021. From March 3 to June 1, 2021, 136 (88%) units were implanted into 113 recipients aged 24-87 years in 18 states (some individuals received multiple units). The remaining 18 units (12%) were located and sequestered. 87 (77%) of 113 identified product recipients had microbiological or imaging evidence of tuberculosis disease. Eight product recipients died 8-99 days after product implantation (three deaths were attributed to tuberculosis after recognition of the outbreak). All 105 living recipients started treatment for tuberculosis disease at a median of 69 days (IQR 56-81) after product implantation. M tuberculosis was detected in all eight sequestered unused units tested from the recalled donor lot, but not in lots from other donors. M tuberculosis isolates from unused product and recipients were more than 99·99% genetically identical. INTERPRETATION: Donor-derived transmission of M tuberculosis via bone allograft resulted in substantial morbidity and mortality. All prospective tissue and organ donors should be routinely assessed for tuberculosis risk factors and clinical findings. When these are present, laboratory testing for M tuberculosis should be strongly considered. FUNDING: None.
引用
- Schwartz NG, Hernandez-Romieu AC, Annambhotla P, et al. Nationwide tuberculosis outbreak in the USA linked to a bone graft product: an outbreak report. Lancet Infect Dis. 2022. PMID: 35934016. doi:10.1016/S1473-3099(22)00425-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。